Medtronic: A Returning Friend at CIIE Unveils New Innovations and Files IPO Prospectus

ShanghaiNovember 6, 2022PR Newswire -- As a global leader in medical technology, Medtronic, a "regular" at the CIIE, is participating for the fifth consecutive year. Among more than 70 exhibits, Medtronic's Patient Monitoring business has brought its most advanced global monitoring solutions to this year’s event, actively engaging with healthcare professionals across various fields to exchange knowledge on cutting-edge therapies and jointly building a protective barrier for life.

Patient monitoring products covering various application scenarios

Medtronic Patient Monitoring at CIIE Booth

As we all know, some complications caused by surgery or medical treatment can not only be life-threatening but also extremely costly to treat. Medtronic's patient monitoring products safeguard the lifeline of more than 100 million patients worldwide each year, preventing high-risk complications and effectively controlling treatment costs.

At this year's CIIE, Medtronic's exhibition theme is "Insight into Life, Unveiling the Extraordinary." Patient monitoring aligns closely with this theme, showcasing a variety of monitoring applications for different scenarios. For example, in perioperative monitoring, the BIS™ Brain Monitoring System and INVOS™ Cerebral and Regional Oximetry System protect vital organs like the brain throughout surgical care and help prevent complications. In pulse oximetry management, the Nellcor™ monitor provides real-time and effective monitoring data for pediatric and adult critical care patients, especially in challenging clinical situations such as low perfusion. In respiratory function monitoring, the Microstream™ Microstream Capnography Monitor is designed for non-intubated patients, effectively reducing adverse events caused by respiratory depression during procedures like painless gastroscopy and hysteroscopy, offering clinicians professional insights for quicker intervention.

BioBotton (This product has not yet been launched in China)

At the same time, Biobutton^TMThe debut of wearable multi-parameter monitoring devices also brings limitless possibilities.

At the 2021 International Consumer Electronics Show (CES), BioButton^TMAwarded the Best Innovation Award, highlighting the product's revolutionary innovation in technology—from "wired" to "wearable"—providing a reliable medical tool for "remote" healthcare. Meanwhile, the product has been approved by the U.S. FDA for market release and is now being introduced to Chinese audiences for the first time by Medtronic Patient Monitoring at the CIIE.

Biobutton^TMIt is a wearable multi-parameter monitoring device that has reached medical grade. Its size is only slightly larger than a one-yuan coin, and when attached to the patient's chest, it can monitor up to 1,440 sets of vital sign parameters daily, including skin temperature, respiratory rate at rest, and heart rate, with a maximum continuous operating time of 30 days.

BioButton^TMMonitoring can span the entire process of medical supervision, following patients from the operating room, intensive care unit, to general in-hospital care, outpatient home care, and even through various scenarios of healthy living. Innovative technologies will ensure the continuous generation of high-quality, medical-grade data across all scenarios, providing real-time, seamless feedback to healthcare professionals via mobile apps or dedicated data transmission components. This empowers doctors with actionable clinical insights, supports clinical decision-making, and enables personalized healthcare.

A Heavyweight Strategic Collaboration through a Powerful Partnership

Since its establishment, Medtronic has been committed to providing market-leading technologies to its customers. At this year's CIIE, in addition to bringing advanced patient monitoring solutions to the Chinese audience, Medtronic also launched a strategic collaboration initiative with GE Healthcare, leveraging its robust innovation platform and extensive business network.

Medtronic Patient Monitoring and GE Healthcare China Strategic Cooperation Signing Ceremony Group Photo

On November 6, at the CIIE venue, Medtronic Patient Monitoring and GE Healthcare China signed a strategic memorandum on innovative cooperation in the joint application of patient monitoring technology. — In recent years, Medtronic and GE Healthcare have continuously carried out various technical collaborations around clinical monitoring solutions. This includes the next-generation GE Healthcare CARESCAPE launched in June this year.^TMTaking the monitoring platform as an example, it is through the deployment of two innovative monitoring solutions from Medtronic—INVOS^TMCerebral and Regional Tissue Oxygen Saturation and Microstream^TMMicrostream CO2 monitoring technology can detect signs of patient deterioration earlier, thereby enhancing comprehensive monitoring solutions throughout the entire process from admission to bedside care, transport, and surgery. This helps medical institutions at all levels, including non-public medical institutions, achieve early detection, early diagnosis, and early treatment in a one-stop clinical service (these integrated solutions are not yet available in the Chinese market).

In the future, the two parties will leverage each other's advantageous resources to explore and collaborate, providing more professional and diverse solutions to support a wide range of clinical scenarios in China. This collaboration will promote personalized precision diagnosis and treatment for every patient, continuously expanding the boundaries of healthcare.

"Uninterrupted Continuous Care" Will Truly Be Achieved

Whether it's the collaboration with GE Healthcare or the groundbreaking Biobutton^TMDebut, all point to the important frontier concept in the monitoring field: Continuous Connected Care (CCC). This model, abbreviated as CCC, runs through the entire process of medical monitoring, following patients from the operating room, intensive care unit, to general in-hospital care, out-of-hospital home care, and even various scenarios of healthy living. Innovative technologies will ensure the continuous generation of high-quality medical-grade data across all scenarios, which is transmitted in real time and seamlessly connected to the CCC platform. With the help of artificial intelligence, it empowers doctors with actionable clinical insights, supports clinical decision-making, enables personalized medical care, reduces clinical risks and adverse patient outcomes, and ensures effective support for patients at any time and place.

In the future post-pandemic era, Medtronic Patient Monitoring has already painted an anticipated and confident picture for us. Leveraging CCC, Medtronic will also expand its ecosystem, continuing to uphold innovation in pursuit of its vision for healthcare. With medical technology, it will assist clinicians in making precise medical decisions promptly, safeguarding patient lives at all times across evolving and expanding health monitoring scenarios.